Akamis Bio to Present NG-348 Phase 1 Data
The Cambridge oncology company will present poster data on its intravenous oncolytic immunotherapy at the SITC 2026 meeting in Phoenix.
Updated on Nov. 3, 2026 in Biotech
Akamis Bio, a clinical-stage oncology company headquartered in Cambridge, Massachusetts, will present Phase 1 data for NG-348 in a poster at the Society for Immunotherapy of Cancer Annual Meeting in Phoenix, Arizona, on November 6, 2026. The study assessed safety, tolerability, and preliminary anti-tumor effects of NG-348 monotherapy in patients with metastatic or advanced epithelial tumors refractory to standard therapies.
Why it matters
NG-348 is an intravenously delivered oncolytic immunotherapy designed to drive intratumoral expression of anti-CD3 scFv and CD80, combining direct T cell engagement with oncolysis. The company says the approach offers potential to overcome immunotherapy resistance, a persistent challenge in treating advanced cancers.
The NG-348 poster is abstract #497 and will be displayed during afternoon and evening sessions on November 6 at the Phoenix Convention Center. The announcement does not disclose the trial's efficacy or safety results, which remain unreported until the presentation.
The players
Akamis Bio
Akamis Bio is a clinical-stage oncology company headquartered in Cambridge, Massachusetts, developing immunotherapies for cancer.
Society for Immunotherapy of Cancer (SITC)
SITC is a professional society focused on advancing cancer immunotherapy research, and its annual meeting is a major venue for clinical data presentations.
The details
NG-348 expresses anti-CD3 scFv and CD80 on tumor-cell surfaces, triggering antigen-independent T-cell activation within the tumor microenvironment. The Phase 1 study enrolled patients with metastatic or advanced epithelial tumors that had not responded to standard therapies.
Timeline
November 4-8, 2026: Society for Immunotherapy of Cancer Annual Meeting in Phoenix, Arizona.
November 6, 2026: NG-348 poster presentation at the Phoenix Convention Center, North Exhibition Halls 4-6.
Roadmap
Oncolytic immunotherapies that combine viral tumor killing with T-cell activation are a growing segment of cancer immunotherapy research. NG-348 joins this class of approaches aimed at overcoming resistance to checkpoint-based treatments.
Patients with advanced epithelial tumors who have not responded to standard therapies may eventually have access to a new treatment option if NG-348 advances. The Phase 1 data will indicate whether the approach is safe enough to justify further clinical development.
The takeaway
Oncolytic immunotherapies that directly engage T cells inside tumors represent one strategy for addressing cancers that resist existing treatments. Readers tracking this field should watch for the full NG-348 Phase 1 results once presented.
What happens next
NG-348 poster data is scheduled for presentation at the SITC Annual Meeting on November 6, 2026, in Phoenix, Arizona.
Further reading
Explore more Biotech developments shaping cancer treatment in the United States.
